20.01
20.01 (0%)
As of Oct 13, 2022
Forma Therapeutics Holdings, Inc. [FMTX]
Source:
Company Overview
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our drug discovery expertise has generated a pipeline of product candidates focused on indications with significant unmet patient need. Our pipeline consists of six product candidates, two of which we are pursuing as product candidates for development, FT-4202 for the treatment of sickle cell disease, or SCD, and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer, or mCRPC.
| Country | United States |
| Headquarters | watertown, massachusetts |
| Phone Number | 617-679-1970 |
| Industry | manufacturing |
| CEO | Frank D. Lee |
| Website | formatherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-53 |
| Net Income | $-52.6 |
| Net Cash | $-2.2 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -22.1% |
| Profit as % of Stockholder Equity | -12.7% |
Management Effectiveness
| Return on Equity | -12.7% |
| Return on Assets | -11.1% |
| Turnover Ratio | |
| EBITA | $-53 |
Balance Sheet and Cash Flow Measures
| Total Assets | $475.2 |
| Total Liabilities | $60.7 |
| Operating Cash Flow | $-94.1 |
| Investing Cash Flow | $91.2 |
| Financing Cash Flow | $0.6 |
